Drug Company Sales Reps In India Say Firms Overcharge At Will (India)
This article was originally published in PharmAsia News
Executive Summary
An organization representing a quarter of drug company sales representatives in India accuse the firms of arbitrarily increasing the prices of their products and getting away with it. The Federation of Medical and Sales Representatives' Associations of India made the accusations in notes to leading members of Parliament. The FMRAI said some companies have hiked their prices by as much as 100 times beyond the government-ordered price caps. Some essential or popular medicines have increased by 600 percent over the past nine years, said FMRAI's joint general secretary, who called the recent voluntary price reduction a "great hoax." Authorities have tried to recover some of the alleged overcharges, but drug companies have filed 75 court challenges against the efforts. (Click here for more ) "Medical Reps Accuse Drug Firms Of Overcharging" Business Standard (India) (12/10/07)
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.